SCHEMBL3593117

SCHEMBL3593117

CN1CC(=O)Nc2cccc([NH])c21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.42
BRD4 O60885 3/20 0.41
CREBBP Q92793 3/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
HTR1A P08908 3/20 0.38
ALDH1A1 P00352 2/20 0.37
LMNA P02545 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
NPC1 O15118 2/20 0.36
CYP3A4 P08684 1/20 0.36
GRM5 P41594 1/20 0.36
RAB9A P51151 1/20 0.36
GRM1 Q13255 1/20 0.36
FTO Q9C0B1 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
EPHX2 P34913 1/20 0.36
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31170855 0.81 CRBN (0.44) CRBNBRD4CREBBPKMT2AMEN1
SCHEMBL3593120 0.80 CRBN (0.42) CRBNBRD4CREBBPKMT2AMEN1
SCHEMBL13150917 0.80 CRBN (0.42) CRBNBRD4CREBBPKMT2AMEN1
SCHEMBL30696906 0.80 KMT2A (0.48) CRBNBRD4CREBBPKMT2AMEN1
SCHEMBL26677680 0.80 KMT2A (0.48) CRBNBRD4CREBBPKMT2AMEN1
SCHEMBL13382909 0.78 CRBN (0.40) CRBNBRD4CREBBPKMT2AMEN1
SCHEMBL1549056 0.76 MEN1 (0.52) CRBNBRD4CREBBPKMT2AMEN1
SCHEMBL2345008 0.76 ALOX5 (0.43) CRBNBRD4KMT2AMEN1ALDH1A1
SCHEMBL3588406 0.73 CRBN (0.42) CRBNBRD4CREBBPKMT2AMEN1
SCHEMBL3599451 0.73 PDK2 (0.44) BRD4KMT2AMEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 CRBN 762/4885BRD4 706/4885CREBBP 2015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.